1. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study
- Author
-
Marcos Pereira de Ávila, Murilo Batista Abud, Kariza Aiko Frantz, David Leonardo Cruvinel Isaac, and Alan Ricardo Rassi
- Subjects
Male ,Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,Intraocular pressure ,Triamcinolone acetonide ,Visual acuity ,genetic structures ,Bevacizumab ,Visual Acuity ,Angiogenesis Inhibitors ,Antibodies, Monoclonal, Humanized ,Triamcinolone Acetonide ,Macular Edema ,Retina ,Double-Blind Method ,Ophthalmology ,medicine ,Humans ,Prospective Studies ,Fluorescein Angiography ,Prospective cohort study ,Glucocorticoids ,Intraocular Pressure ,Diabetic Retinopathy ,medicine.diagnostic_test ,business.industry ,General Medicine ,Diabetic retinopathy ,Middle Aged ,medicine.disease ,Fluorescein angiography ,Acetonide ,eye diseases ,Treatment Outcome ,Intravitreal Injections ,Female ,sense organs ,medicine.symptom ,business ,Tomography, Optical Coherence ,Follow-Up Studies ,medicine.drug - Abstract
Purpose: To compare the effect of a single intravitreal injection of triamcinolone acetonide and bevacizumab in reducing macular thickness, which was measured by optical coherence tomography (OCT) in patients with diabetic macular oedema (DMO). Methods: The patients received a single intravitreal injection of 1.25 mg bevacizumab in one randomly selected eye and 4.0 mg triamcinolone acetonide in the contralateral eye. Central foveal thickness measurement (CFT) with OCT was taken at the initial visit and at the 4-week, 12-week and 24-week visits. Results: Eleven patients (22 eyes) were enrolled and statistically analysed. CFT reduced in the eyes treated with triamcinolone and those treated with bevacizumab in weeks 4 and 12 (p
- Published
- 2009
- Full Text
- View/download PDF